These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 7018668)

  • 1. Adoptive therapy of established syngeneic leukemia by cells primarily sensitized in vitro.
    Cheever MA; Greenberg PD; Fefer A
    Cancer Res; 1981 Jul; 41(7):2658-63. PubMed ID: 7018668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapy of leukemia by nonimmune syngeneic spleen cells.
    Cheever MA; Greenberg PD; Fefer A
    J Immunol; 1980 May; 124(5):2137-42. PubMed ID: 7365249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specificity of adoptive chemoimmunotherapy of established syngeneic tumors.
    Cheever MA; Greenberg PD; Fefer A
    J Immunol; 1980 Aug; 125(2):711-4. PubMed ID: 6156213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunochemotherapy of transplantable Moloney leukemia with cyclophosphamide and allogeneic spleen lymphocytes and reversal of graft-versus-host disease with alloantiserum.
    Kende M; Keys LD; Gaston M; Goldin A
    Cancer Res; 1975 Feb; 35(2):346-51. PubMed ID: 234033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spontaneous and IL-2-induced anti-leukemic and anti-host effects against tumor- and host-specific alloantigens.
    Cohen P; Vourka-Karussis U; Weiss L; Slavin S
    J Immunol; 1993 Nov; 151(9):4803-10. PubMed ID: 8409438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 1. Alloimmune-mediated graft-versus-leukemia (GVL) effects induced by unmodified and in vitro rIL-2-activated bone marrow and lymphocytes from different lymphoid compartments.
    Weiss L; Reich S; Slavin S
    Cytokines Cell Mol Ther; 1999 Sep; 5(3):145-52. PubMed ID: 10641572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Syngeneic adoptive immunotherapy and chemoimmunotherapy of a Friend leukemia: requirement for T cells.
    Berenson JR; Einstein AB; Fefer A
    J Immunol; 1975 Jul; 115(1):234-8. PubMed ID: 1080165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of graft-versus-leukemia (GVL) activity in murine leukemia models after IL-2 pretreatment of syngeneic and allogeneic bone marrow grafts.
    Zeis M; Uharek L; Glass B; Gaska T; Gassmann W; Mueller-Ruchholtz W
    Bone Marrow Transplant; 1994 Nov; 14(5):711-5. PubMed ID: 7889004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Occurrence of tumor antigen pRL1a specific CD8 T cells in spleen cells from syngeneic BALB/c, semiallogeneic (BALB/c x C57BL/6)F1 and allogeneic C57BL/6 mice.
    Hata H; Uenaka A; Takada I; Kenjo A; Takahashi M; Ono T; Fujita T; Nakayama E
    Int J Oncol; 2002 May; 20(5):1019-25. PubMed ID: 11956599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor sponge implantation: an in vivo method for studying syngeneic, primary antitumor lymphocyte responses.
    Vallera DA; Mentzer SJ; Maizel SE
    Cancer Res; 1982 Feb; 42(2):397-404. PubMed ID: 7055792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of the in vitro secondary response to syngeneic tumor and of in vivo tumor therapy with immune cells by culture-induced suppressor cells.
    Greenberg PD; Cheever M; Fefer A
    J Immunol; 1979 Aug; 123(2):515-22. PubMed ID: 222839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of secondary cellular immunity to a tumor allograft by cyclophosphamide and 1,3-bis(2-chloroethyl)-1-nitrosourea.
    Einstein AB; Fass L; Fefer A
    Cancer Res; 1975 Mar; 35(3):492-6. PubMed ID: 1078784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-mediated immunogenic changes of virus-induced leukemia in vivo.
    Houchens DP; Bonmassar E; Gaston MR; Kende M; Goldin A
    Cancer Res; 1976 Apr; 36(4):1347-52. PubMed ID: 1260759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemoimmunotherapy of a Friend leukemia with cells secondarily sensitized in vitro: effect of culture duration on therapeutic efficacy.
    Cheever MA; Greenberg PD; Fefer A
    J Natl Cancer Inst; 1981 Jul; 67(1):169-73. PubMed ID: 6942187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymphocytes generated by in vivo priming and in vitro sensitization demonstrate therapeutic efficacy against a murine tumor that lacks apparent immunogenicity.
    Shu SY; Chou T; Sakai K
    J Immunol; 1989 Jul; 143(2):740-8. PubMed ID: 2738408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eradication of residual disease by administration of leukemia-specific T cells after experimental allogeneic bone marrow transplantation.
    Zeis M; Uharek L; Glass B; Vosskötter W; Dreger P; Schmitz N; Steinmann J
    Exp Hematol; 1998 Oct; 26(11):1068-73. PubMed ID: 9766447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adoptive immunotherapy in tumor-bearing mice with OK-432-induced killer cells.
    Ujiie T
    Jpn J Exp Med; 1988 Apr; 58(2):109-14. PubMed ID: 3261814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of tumor cells modified by trinitrobenzene suflonic acid (TNBS).
    Kedar E; Unger E; Galili N; Klein G; Asjo B; Bonavida B; Naor D
    Prog Clin Biol Res; 1976; 9():109-21. PubMed ID: 1030796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Photodynamic therapy-mediated immune response against subcutaneous mouse tumors.
    Korbelik M; Dougherty GJ
    Cancer Res; 1999 Apr; 59(8):1941-6. PubMed ID: 10213504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclophosphamide-induced appearance of immunopotentiating T-cells in the spleens of mice bearing a large MOPC-315 tumor.
    Ye QW; Mokyr MB
    Cancer Res; 1984 Sep; 44(9):3873-9. PubMed ID: 6611201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.